A survey of United States dermatologists' knowledge, attitudes, and practices with intramuscular triamcinolone.

Autor: Kuceki G; Department of Dermatology, University of Utah, 30 N 1900 East, 4A330, Salt Lake City, UT, 84132, USA., Snyder AM; Department of Dermatology, University of Utah, 30 N 1900 East, 4A330, Salt Lake City, UT, 84132, USA.; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA., Hopkins ZH; Department of Dermatology, University of Utah, 30 N 1900 East, 4A330, Salt Lake City, UT, 84132, USA., Secrest AM; Department of Dermatology, University of Utah, 30 N 1900 East, 4A330, Salt Lake City, UT, 84132, USA. aaron.secrest@hsc.utah.edu.; Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA. aaron.secrest@hsc.utah.edu.; Department of Dermatology, Canterbury District Health Board, Health New Zealand, Christchurch, New Zealand. aaron.secrest@hsc.utah.edu.
Jazyk: angličtina
Zdroj: Archives of dermatological research [Arch Dermatol Res] 2023 Sep; Vol. 315 (7), pp. 1995-2002. Date of Electronic Publication: 2023 Mar 05.
DOI: 10.1007/s00403-023-02596-4
Abstrakt: Since the 1970s, intramuscular triamcinolone (IMT) has been available as an option for systemic corticosteroid use in dermatology. Although shown to be safe and effective in early studies, this method of systemic corticosteroid delivery fell out of favor in the 1980s in many United States residency programs. To identify factors associated with US dermatologists' preferences for and use of IMT we surveyed a random sample of US board-certified dermatologists to assess knowledge, attitudes, and practices regarding IMT in dermatologists' daily clinical practice. A total of 844 out of 2000 dermatologists completed the survey (42.2%). Only 55.0% reported feeling comfortable using IMT for steroid-responsive dermatoses, while 90.4% felt comfortable using oral corticosteroids for steroid-responsive dermatoses. Most participants (59.2%) did not prefer IMT over oral corticosteroids when both were indicated. One third (33.3%) of the participants reported that none of the faculty during their residency advocated using IMT. Receiving education on IMT indications (OR = 1.96 [95% CI: 1.46-2.63]) and encouragement to use IMT (OR = 4.29 [95% CI: 3.01-6.11]) during residency were positively associated with use of IMT at least once a month in current practice. Current knowledge, attitudes, and practices surrounding IMT vary amongst practicing dermatologists. Modifiable factors such as training could improve comfort with use of this short-term systemic steroid treatment modality.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: